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Abstract  
Background 
The EuroQol-Five Dimension (EQ-5D) is the National Institute for Health and Care Excellence 
1,&(¶VSUHIHUUHGPHDVXUHRIKHDOWK-related quality of life (QoL) in adults. The 3-level (3L) value 
set is currently recommended for use, but the 5-level (5L) is increasingly being used in practice. We 
aimed to explore the impact of moving from 3L to 5L in NICE appraisals. 
Methods 
We adapted our existing mapping for use with health state utility values derived from a population 
where the original distribution of utilities was unknown. We used this mapping to estimate 5L utilities 
for 21comparisons of interventions from models used in NICE technology appraisal decision-making, 
covering a range of disease areas. 
Results  
All utilities increased using 5L, and the differences between highest and lowest utilities decreased. In 
10 oncology comparisons, using 5L generally increased the incremental quality-adjusted life years 
(QALYs) as the benefit from improving survival increased. In 4 non-oncology comparisons where the 
intervention improved QoL only, the incremental QALYs decreased as the benefit of improving QoL 
was reduced. In 7 non-oncology comparisons where interventions improved survival and QoL, there 
was a trade-off between increasing the benefit from survival and decreasing the benefit from 
improving QoL.  
 
Conclusion 
3L and 5L lead to substantially different estimates of incremental QALYs and cost-effectiveness. The 
direction and magnitude of the change is not consistent across case studies. Using 5L instead of 3L 
may lead to different reimbursement decisions. NICE will face inconsistencies in decision-making if 
it uses 3L and 5L concurrently.  
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Key Points for Decision Makers  
x Our mapping can be used to convert mean 3L utilities into 5L utilities for use in economic 
models 
x Using 5L instead of 3L in economic models slightly decreases ICERs for interventions that 
improve survival, but can substantially increase ICERs for interventions that only or primarily 
reduce morbidity 
x Using 5L instead of 3L will lead to different decisions about cost-effectiveness and this 
cannot be rectified by applying a simple adjustment to the ICERs below which interventions 
are cost-effective  
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1 Introduction 
The EQ-'LVWKH1DWLRQDO,QVWLWXWHIRU+HDOWKDQG&DUH([FHOOHQFH1,&(¶VSUHIHUUHGPHDVXUHRI
health-related quality of life in adults[1]. NICE currently states that the EQ-5D 3 Level (3L) value set 
should be used and not the EQ-5D 5 Level (5L) value set, although a review of this statement is 
planned for 2018[2]. It has been claimed that the descriptive system of 5L is superior to 3L[3] and 
other studies suggest that 5L has increased sensitivity and precision[4, 3]. Given the increasing use of 
5L in practice, it is important to determine the impact of moving from 3L to 5L in economic 
evaluation. To do this, we use statistical mapping to convert existing evidence compiled on a 3L basis 
to the new 5L basis. 
We have previously developed methods for mapping between 3L and 5L and demonstrated that they 
do not generally give the same results when used in cost-effectiveness analyses conducted alongside 
clinical trials[5].  In that publication, we showed that 5L shifts mean scores up the utility scale 
towards full health and compresses them into a smaller range, compared to 3L. In 13 comparisons 
from nine case studies based on direct observation of 3L at the individual level, we found that 
mapping to 5L increased incremental cost-effectiveness ratios (ICERs) for most interventions, with 
one notable exception where the intervention substantially improved survival[5]. There is therefore a 
need to further explore the comparison between interventions that improve quality of life only and 
interventions that improve survival. Case studies from the NICE Technology Appraisal (TA) 
programme are of particular interest, given their relevance to decision making and reimbursement in 
(QJODQGDQG1,&(¶VUHTXLUHPHQWIRUVXFKZRUNWRLQIRUPWKHLUSRVLWLRQRQWKHXVHRI(4-5D[2].  
In our previous work, the mapping model was used to convert observed 3L health descriptions to 5L 
utilities, but it can also be used to convert 3L utilities to 5L utilities [5] in cases where the underlying 
3L health descriptions are not available.   
Our aim was to explore the impact of moving from 3L to 5L in NICE TAs and how that impact might 
differ across the range of disease areas considered by NICE¶V7$SURJUDPme. Since economic 
evaluation for most TAs involves economic models using mean utilities for health states, we needed 
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to apply our method for mapping mean utilities. The analysis presented here is in two parts. First we 
develop a strategy for using our mapping model to convert  mean 3L utilities to 5L. We then use this 
strategy to explore the impact of using mapped 5L utilities instead of 3L utilities in a range of 
HFRQRPLFPRGHOVWKDWKDYHEHHQXVHGLQ1,&(¶V7$SURJUDPPH 
2 Methods 
2.1 Mapping 
Data 
Our mapping method uses econometric models estimated from either of two datasets: the EuroQol 
Group international coordinated study (EQG) (n=3551) and the US-based FORWARD databank  
(n=5205). The EQG dataset contains 3L and 5L responses for a sample drawn from eight broadly 
defined disease groups and a healthy population. The FORWARD dataset samples patients with 
rheumatoid disease and contains 3L and 5L responses and responses to many other general and 
rheumatoid disease specific questions. The 3L and 5L responses are converted into utilities using the 
standard value sets for the UK / England[6, 7]. The 3L and 5L value sets have been discussed 
elsewhere, where analysis found that the distribution of value sets differed, with 5L values higher than 
3L values, a smaller range of 5L values and less difference between adjacent states in 5L[8]. Further 
information on the FORWARD and EQG datasets is provided elsewhere[5, 9].  
Our mapping jointly models responses to the five domains of 3L and 5L. The model is very flexible to 
allow the 3L and 5L responses within each domain to be strongly correlated, but the strength of the 
relationship to vary by severity of illness, by using one of five different copulas (functions which 
describe the dependence between variables). The model also allows the relationship between 3L and 
5L to vary between domains, and accommodates common factors linking response behaviour across 
domains. It allows for the effect of age and sex without assuming they influence 3L and 5L in the 
same way [10]. Within and out-of-sample testing of the mapping model found no significant concerns 
and the biases often seen in mapping studies applying simplistic methods were not present[11]. 
Because we are modelling responses to the descriptive systems, the mapping is not biased by the 
health or preferences of people within the datasets from which the mapping was derived.  
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The 3L and 5L utility value scales are non-linear, so it is not appropriate to map the 3L response to the 
most likely 5L response, and then to value that response using 5L ± such a procedure would introduce 
bias. Instead, when individual responses are available, the model is used to generate the probability of 
HDFKSRVVLEOHFRQILJXUDWLRQRI/UHVSRQVHVIRUHDFKLQGLYLGXDO¶V/UHVSRQVHWKHQDSSOLHVWKH/
utility scale to each of those responses; and then weights each possible score according to the 
probability of that response to give the predicted (conditional mean) 5L utility score for each 
individual.  
In cases where only the 3L utility and not the response to each domain is known there may be 
multiple 3L responses that correspond to this utility (since the valuation of 3L response combinations 
are not necessarily unique). Alternatively, the 3L utility may not correspond to any of the utilities for 
the 243 health states, for example if another measure has been mapped to 3L and an approximate 
utility has been estimated, or where the 3L utility is the mean of a sample of individual patient 
utilities. In these situations, the mapping can consider a range around the 3L utility under 
consideration and search within this range for valid 3L utilities. The user must specify the range 
around the 3L utility in which the model should search for valid 3L utilities ± this range is termed the 
µEDQGZLGWK¶If there is only one valid 3L value within the bandwidth, the model uses this as a valid 
and unique 3L utility. If there are multiple 3L utilities within the bandwidth, the model assigns a 
weight to each utility based on its distance from the input utility, such that more weight is given to 
closer values. Each of these nearby 3L values is then mapped to 5L as described above, and the 
mapped 5L utility is calculated as the weighted average. A full technical description of the mapping 
model, with guidance on its use, is provided elsewhere [10, 12].    
Analysis 
In cost-effectiveness models, often the utility used for a population health outcome is the mean of a 
set of utilities from an unknown range, and the mapping then needs to be used appropriately to reflect 
this. If we knew the true distribution of the 3L utilities that form the mean, we could map each 
individual 3L utility to 5L and then calculate the mean for 5L. Information on the true distribution 
will rarely be available so instead we use weighted averaging of 5L utilities calculated by mapping 
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every valid 3L utility within a range of the utility used in the economic model. The size of this range 
is defined by the user-specified bandwidth. A smaller bandwidth averages the 5L predictions 
corresponding to a more localised part of the 3L utility scale; a larger bandwidth averages over a 
broader range of the 3L utility scale. To develop a strategy for choosing the bandwidth, we analysed 
the EQG and FORWARD datasets to compare actual 5L utilities with values mapped from mean 3L 
utilities, exploring the effect of varying bandwidth sizes. Using the more detailed and homogenous 
patients in the FORWARD dataset, we carried out the analysis separately for each of eleven 
subgroups, categorised by patient global assessment of disease severity.  
2.2 Case studies 
Data  
We selected 20 case studies of models used in NICE TA decision making representing the range and 
type of technologies and disease areas typical of the TA programme.  Each of the economic models 
used in the case studies was based predominantly, but not exclusively on 3L utilities (since it is often 
not possible to find EQ-5D values for all utility inputs in a model, limiting to exclusively 3L would 
have dramatically reduced the number of potential case studies). For all cases, final guidance had been 
produced, ICERs were reported in the guidance, and the role these ICERs played in developing 
recommendations was clear. In selecting case studies, we initially reviewed a list of models critiqued 
or developed by two Assessment Groups, and selected case studies that met the above criteria. We 
then discussed the selected case studies with NICE staff, who advised other indications that should be 
considered, based on their experience of working on a number of appraisals, and so we reviewed a list 
of past TAs to identify potential suitable topics. We considered that our approach reflected a 
pragmatic cross section of the types of interventions considered by NICE, and sufficiently large to 
draw general conclusions. A comparison of the distribution of our case studies and all NICE TAs 
from TA001 to TA516 across International Classification of Diseases-10 classifications is shown in 
Figure 1. We negotiated access to the models via NICE and the relevant Assessment Group and 
gained access and permission to use all of the case studies we requested. 
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Seventeen of the 20 cases were Single Technology Appraisals (STAs).  We focussed on the 
technology under appraisal and the primary comparator reported in the final guidance. Two cases 
were Multiple Technology Appraisals (MTAs): in one case only one comparison was considered (the 
new technology dominated other comparators); in the other case we considered three interventions, 
drawing pairwise comparisons between the least effective and next least effective, and the latter with 
the most effective. Additionally, we considered one case study from the Highly Specialized 
Technology (HST) programme. Therefore, we considered 21 comparisons.  
Analysis  
In each model, we mapped 3L utilities to 5L utilities using the Stata command EQ5DMAP, for a 
range of bandwidth values depending upon the 3L utility. We only mapped utilities which were stated 
as being derived from 3L data, so values from other preference-based measures, expert opinion, or 
unclear sources were not mapped (these were generally more minor aspects of the analyses). We used 
both EQG and FORWARD-based versions of the mapping. We used the most general version of the 
mapping model, which uses the best fitting copula in each domain[9].  
We calculated total and incremental quality-adjusted life years (QALYs) for the intervention and 
comparator using mapped 5L utilities, and then calculated ICERs. We analysed the change in 
incremental QALYs and ICERs for comparisons in three categories: 
x Oncology interventions that improved survival (10) 
x Non-oncology interventions that improved survival (4) 
x Non-oncology interventions which did not improve survival (7). 
We explored differences within and across categories, to understand general tendencies in terms of the 
settings in which mapping to 5L may increase QALY gains and those in which QALY gains may 
decrease. We compared the ICERs to the range of maximum acceptable ICERs specified in the NICE 
Methods Guide[1] and conducted scenario analyses to explore the impact of mapping disutilities. 
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3 Results 
3.1 Mapping 
The mean directly-observed 5L utilities in the EQG and FORWARD datasets (0.712 and 0.778) were 
compared to 5L utilities produced by mapping the mean 3L utility (0.628 and 0.681), using varying 
bandwidths to perform the mapping. We found that small bandwidths (less than 0.1) returned 5L 
estimates very close to those observed (largest difference 0.023 for EQG and 0.028 for FORWARD). 
For EQG, the mapping slightly overestimated the mean 5L utility as the bandwidth increased towards 
0.3 (largest difference 0.047), and then decreased towards the actual utility at a bandwidth of 
approximately 0.4. Above the (very large) bandwidth value of 0.4, the mapped mean EQG utility 
declined, falling further below the actual mean (largest difference 0.196 at a bandwidth of 1). This is 
primarily because, with a larger bandwidth, the mapping can include utilities much lower than the 
mean 3L utility, but cannot include utilities much higher as they are capped at 1. For FORWARD, the 
mapped utilities remained close to the actual mean as the bandwidth increased towards 0.32 (largest 
difference 0.025). Above 0.32 the estimated mean utility declined further below the actual mean, for 
the same reason as EQG (largest difference 0.253 at a bandwidth of 1).  
To determine appropriate bandwidths for a range of mean 3L values, we performed the same analysis 
as described above for eleven severity groups of the FORWARD data, categorised by the Rheumatoid 
Arthritis Patient Global Assessment.  The patient global assessment is included in the American 
College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Rheumatoid 
Arthritis remission criteria[13]. The version used in the FORWARD is the 21 point numerical rating 
scale version of a Visual Analogue Scale. The inclusion of this variable in the FORWARD dataset 
permitted us to mimic analyses for datasets with different average levels of illness severity while 
retaining much of the individual variability in EQ-5D scores typically observed.  There is substantial 
variation in EQ-5D utilities within each severity group, so choice of bandwidth has an effect. The 
detailed results are shown in Figure 2 and suggest the following bandwidth strategy, which we have 
followed in our analysis of the case studies. 
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(1) For mapping a 3L utility in the gap between full health (1.0) and the next feasible 3L value 
(0.883), the bandwidth should be just large enough to reach 1.   
(2) For 3L utilities in the range 0.883 to 0.7 (inclusive), smaller bandwidths are preferable and 
should not exceed 0.1. In our application we use a bandwidth of 0.05. 
(3) For 3L utilities below 0.7 down to 0.6, a bandwidth of 0.2 is recommended. 
(4) For 3L utilities below 0.6, a larger bandwidth is appropriate; we recommend the value 0.4.  
 
3.2 Case studies 
In each case study we replaced the 3L utilities which were used in the original economic models by 
5L utilities mapped from them. The results are summarised by Figure 3 in terms of the changes to 
estimates of incremental QALYs and by Figure 4 in terms of the corresponding ICERs. Three case 
studies are omitted from Figure 3 and Figure 4 as their results are confidential.  
The switch to 5L increased utilities in all cases with one exception (where the 3L utility was 1), using 
both the EQG and FORWARD datasets for mapping to 5L. We observed a general tendency for the 
increase in utility to be larger for EQG-based mapping than for FORWARD-based mapping if the 3L 
utility was high (around 0.8 or higher), but smaller if the 3L utility was low (0.8 or below). 
Consequently, the choice of reference dataset used for mapping has some bearing on the results, and it 
may affect studies based on populations with different mean utilities in different ways. Since all 
utilities increased when mapped to 5L, the total QALYs for intervention and comparator groups in 
each case study also increased. However, the difference between the lowest and highest utility in each 
case study decreased after mapping to 5L. This is a consequence of the more compressed range of the 
5L value set and is consistent with previous results reported in Hernandez et al[5].  It means that the 
incremental QALY gain will increase for an intervention which derives all its benefit from improving 
survival, but decrease for an intervention which derives all its benefit from improving quality of life. 
The interventions in the four non-oncology comparisons which did not improve survival are examples 
of the latter type of intervention, and Figure 3 shows that all of their incremental QALY gains 
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decreased using 5L. The mean change in incremental QALYs was -29.0% for EQG (range: -41.6%, -
16.2%) and -44.9% for FORWARD (range: -55.2%, -24.4%).    
The interventions in the other 17 comparisons derived their incremental QALY gain from a 
combination of improving survival and improving quality of life. This meant that in some cases the 
QALY gains increased, and in other cases the QALY gains decreased (see Figure 3).  
For the ten comparisons for oncology interventions, the mean change in incremental QALYs was 
8.3% for EQG (range: 0.5%, 15.2%) and 7.3% for FORWARD (range: -7.3%, 16.2%). The 
incremental QALY gain decreased using 5L in only one case study, and then only when FORWARD-
based mapping was used. In that case study, utilities were defined by pre- and post-progression and 
were higher for the intervention than comparator group. Patients receiving the intervention spent 
longer in the pre-progression state than patients receiving the comparator, but less time in the post-
progression state. Using 5L, the utilities for the pre- and post-progression states all increased, but the 
increase was greater for post-progression than for pre-progression states. Although the switch to 5L 
caused an increase in the QALY gain from spending more time in pre-progression and delaying death, 
with FORWARD-based mapping, it was offset by a decrease in the QALY gain from keeping people 
in pre-progression instead of post-progression.  
In all other comparisons from the oncology case studies, the increases in QALY gain from improving 
survival outweighed the decrease in QALY gain from delaying progression. Two oncology case 
studies modelled utility by time to death rather than pre- and post-progression: in each case the 
intervention increased the time spent in the health state furthest from death and patients on 
intervention and comparator spent approximately the same time in the other health states. The 
magnitude of the increase in incremental QALYs in these cases therefore depended only on the 
magnitude of the increase in the utility of the health state furthest from death.  
For the seven comparisons for non-oncology interventions which improved survival, the mean change 
in incremental QALYs was -12.0% for EQG (range: -38.8%, 5.0%) and -19.8% for FORWARD 
(range: -53.5%, 6.6%). The use of mapped 5L utilities slightly increased the incremental QALYs for 
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two case studies: one in circulatory system disorders and one in musculoskeletal disease. The 
incremental QALYs decreased or only marginally changed (less than 0.002) for the other four case 
studies, which considered mental and behavioural disorders, nervous system diseases, musculoskeletal 
diseases, infections and metabolic disorders. As shown in Figure 3, there was no relationship between 
the size of 3L incremental QALYs and the direction of change. It is therefore not possible to draw 
general conclusions on the basis of disease area or of 3L incremental QALYs.  
In most case studies, we did not map the disutilities associated with adverse events because the source 
of the disutility was not EQ-5D or was not reported. Where we did map adverse events, the incidence 
of adverse events was higher for comparator than intervention groups, and mapping the disutility to 
5L decreased its size, so the incremental benefit of the intervention was reduced. To further explore 
the impact of disutilities, we considered one case study which included disutilities for disease-related 
exacerbations, adverse events and caregiver burden. Leaving these disutilities unchanged but mapping 
the primary health states led to decreases in QALYs gained of 72% (EQG) and 64% (FORWARD). 
Including all disutilities further decreased health gain to 61% (EQG) and 47% (FORWARD).  
Figure 4 shows changes in ICERs. These ranged from a decrease of 13.23% to an increase of 7.89% 
for oncology interventions that improved survival (mean decrease of 8.61% EQG and 5.57% 
FORWARD); from a decrease of 6.22% to an increase of 115.16 % for non-oncology interventions 
that improved survival (mean increase of 13.02% EQG and 28.02% FORWARD); and from an 
increase of 22.14% to an increase of 123.44% for non-oncology interventions that did not improve 
survival (mean increase of 53.5% EQG and 108.3% FORWARD). 
 
4 Discussion 
Mapping from 3L to 5L shifts the distribution of utilities upwards, towards full health and compresses 
them into a smaller range.  This means that, for an intervention that only improves survival and does 
not improve quality of life, there is a tendency for the incremental QALYs to increase (and ICERs to 
decrease) when 5L is used. The increase in QALYs will generally be larger using FORWARD than 
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using EQG. For an intervention that only improves quality of life by delaying or avoiding disease 
progression and does not improve survival, incremental QALYs will decrease when 5L is used. The 
decrease in QALYs will usually be larger when using FORWARD rather than EQG based mapping. 
Many interventions improve both quality of life and survival, so there is a trade-off between the gain 
in incremental QALYs from improving survival and the decrease in incremental QALYs from 
reducing the benefit of delayed progression.  
Our findings echo previous research findings that 3L and 5L lead to different estimates of cost-
effectiveness, and that switching to 5L typically increases ICERs for interventions that do not extend 
life[5]. Our research expands on this by applying mapping in the context of model-based rather than 
individual-based direct evaluation. We also consider a wider range of case studies of interventions, 
including 17 that extend life. Other research has found that compared to 5L, 3L overestimates health 
problems and therefore underestimates utility scores[3], consistent with our findings that utility values 
increase using 5L. The increased sensitivity and precision of 5L compared to 3L[3], and in particular 
the reduction in ceiling effects[4], may be expected to result in greater changes in utility using 5L, and 
hence higher QALY gains, but instead we found that 5L reduced the difference between best and 
worst health states. -DQVVHQHWDO¶V comparison of 3L and 5L in seven countries found that while 3L 
had better discriminatory power between healthy versus disease states, 5L had better discriminatory 
power between mild and moderate/severe states[3]. In the examples considered in our case studies, 
the utilities for the health states were closer to the healthy and mild states than severe states in the 
study by Janssen et al, so it is unsurprising that the difference between the health state utility values 
decreased.   
We demonstrate that the use of 5L may slightly decrease the ICERs for life-extending interventions 
(although they can increase) and can substantially increase the ICERs for interventions which only or 
primarily improve quality of life. Due to variation in the magnitude and direction of change in ICERs, 
it is not possible to define a simple adjustment that could be applied to the range of maximum 
acceptable ICERs that is used for determining whether interventions are cost-effective when 5L is 
used and that would be consistent with decisions based on 3L.  
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We have seen that the ICERs for a few interventions are below a £20,000-£30,000 range using 3L, 
and above this range using 5L, demonstrating that using 3L and 5L concurrently may lead to 
inconsistencies in decision-making[1]. Policy decisions about 3L versus 5L will impact real patients 
and their treating clinicians.  
Our study only included case studies that primarily used EQ-5D, and only mapped the inputs in those 
case studies that clearly used EQ-5D. Although EQ-5D is the stated preferred measure of health-
UHODWHGTXDOLW\RIOLIHLQ1,&(¶VUHIHUHQFHFDVH[1], it is not necessarily used in all appraisals. It could 
be argued that since non-EQ-5D utilities in NICE appraisals are being treated as if they are EQ-5D 
that they should also be mapped to 5L. Previous research has explored the differences between 3L and 
other preference-based measures of health [14-18], but no such studies exist for 5L.  In situations 
where utilities (or more commonly disutilities for adverse events) were elicited from experts, if the 
experts are assumed to have estimated these based on the 3L utility system, then arguably the utilities 
should be mapped. Alternatively, if the experts are assumed to have estimated these based on 
understanding the concept of utility scores without referring to specific quality of life measures,  then 
arguably the values should not be mapped.  
Our approach to selecting case studies was pragmatic rather than systematic ± in addition to 
representing a range of disease areas and using EQ-5D, selection was influenced by date of 
publication and suggestions from the project team. The decision to stop after 20 case studies was 
taken once the results for 20 had been summarised, and the project team felt that conclusions were 
unlikely to change with the addition of more case studies. In the comparison in Figure 2, our case 
studies tend to generally reflect the areas covered by NICE TAs. Neoplasms is the classification with 
the most appraisals ± this is higher in our analysis than in all appraisals considered by NICE as we 
wanted to include case studies with a range of QALY and survival gains. Furthermore, the proportion 
of NICE TAs which are oncology has increased in recent years, and we wanted to reflect current and 
future practice. Figure 2 appears to indicate that we do not consider any case studies of eye 
conditions, but one of our case studies considers diabetic macular oedema, which is classified as an 
endocrine disorder, but the economic modelling is based around visual acuity. Our analysis does not 
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contain any case studies in respiratory conditions whereas there are several NICE TAs in this area, but 
we note that several of these are in influenza where EQ-5D was not used. We have a lower proportion 
of musculoskeletal conditions and a higher proportion of mental and behaviour disorders, but consider 
WKDWRXUFDVHVWXGLHVGRUHIOHFWWKHUDQJHRIGLVHDVHFRQVLGHUHGLQ1,&(¶V7$SURJUDPPH However, it 
is important to note that we do not make general conclusions about the relationship between disease 
area or incremental QALYs using 3L and the magnitude or direction of change using 5L and instead 
report the impact of interventions that improve survival and/or reduce morbidity. Therefore, our 
findings are not dependent upon the selected case studies, and as such our case study selection process 
is unlikely to have biased our results. Our findings and conclusions apply to any scenario where an 
intervention improves survival, reduces morbidity or both.  
Of course, all results are subject to the underlying data used to map the two EQ-5D variants. There are 
several limitations to both datasets[9] and a programme of work is being undertaken by NICE and the 
Department of Health and Social Care in the UK to address these uncertainties[5].  
5 Conclusion 
5L and 3L lead to very different assessments of cost effectiveness. Consistent with analyses 
conducted using case studies based on economic evaluations alongside trials we find that the impact 
on NICE TAs of moving from 3L to 5L could be profound. The ICERs for interventions that improve 
survival can decrease using 5L, but by a relatively small degree. However, it is not possible to predict 
whether the counter effect of decreased QALY gain from any additional morbidity effect will 
decrease or increase ICERs. Appraisals of technologies that only improve morbidity can see very 
large increases in ICERs using 5L, in some cases these more than double.  
The 5L is not simply an extended version of the 3L. Differences in both descriptive systems and 
valuation methods mean the two cannot be treated as if they were interchangeable. A move to 5L will 
lead to different decisions than would have been the case under 3L. There is no simple proportional 
adjustment, such as changing the range of ICERs below which interventions are considered to be cost-
effective, that could rectify this conundrum. Future changes to NICE policy need to be aware of this 
information in order to ensure decision making is consistent, fair and reflects scientific state of the art. 
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If in the future NICE determines that 5L should be used instead of 3L, our mapping can be used to 
convert 3L utilities to 5L utilities in economic models. 
 
Data Availability Statement 
The models used in the current study are not publically available as they formed part of companies' 
submissions to NICE.  
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Figure captions and legends 
Figure 1: Distribution of case studies and NICE appraisals across International Classification of 
Disease-10 categories 
NICE: National Institute for Health and Care Excellence 
 
Figure 2: FORWARD data classified by severity: actual and mapped means of 5L utility, using 
different bandwidths for mapping from 3L mean utility 
3L: EuroQol-5 Dimension-3 Level. FORWARD: National Data Bank for Rheumatic Diseases. 
 
Figure 3: Incremental Quality Adjusted Life Years using 3L and 5L 
3L: EuroQol-5 Dimension-3 Level. 5L: EuroQol-5 Dimension-5 Level. EQG: EuroQol Group 
coordinated study. FORWARD: National Data Bank for Rheumatic Diseases. 
 
Figure 4: Incremental Cost-Effectiveness Ratios using 3L and 5L 
3L: EuroQol-5 Dimension-3 Level. 5L: EuroQol-5 Dimension-5 Level. EQG: EuroQol Group 
coordinated study. FORWARD: National Data Bank for Rheumatic Diseases. 
 
 
